Clinical Trials Browser

Phase 2 × Recurrence × Brentuximab Vedotin × Clear all

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Phase 2 Recruiting

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02388490 2024-09-23

Bretuximab

Phase 2 Completed

25 enrolled 12 charts

Lymphoma, Recurrence

NCT03474133 2020-07-21

BASALT

Phase 2 Unknown

Hodgkin Disease, Recurrence